1.	Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCNONCO200801, NCT00777504
2.	Biological, Pathological and Imagery Markers in the First-Line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P070104, NCT00930345
3.	A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001LIC01, NCT01206764
4.	An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRAD001LDE36T, 2010-021370-11, NCT01266837
5.	Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: SG 327/10, NCT01402089
6.	Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001LDE43, 2011-003416-23, NCT01514448
7.	First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and ove Sponsor: Other Protocol IDs: iOM-605, 2011-001138-40, NCT01521715
8.	Prospective Randomized Study Comparing Laparoscopic Versus Open Partial Nephrectomy Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UROUSP - 005, NCT01809119
9.	SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181034, UCLA-0406015-01, PFIZER-A6181034, NCT00083889
10.	A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181109, NCT00375674
11.	Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: MRC-RE05-SORCE, MRC-RE05-SORCE, EUDRACT ID 2006-006079-19, EU-20734, NCT00492258, SORCE, ISRCTN38934710
12.	Trial of Collagen Mesh for Prevention of Ventral Hernia After Surgery for Advanced Pelvic Cancer Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: VRAM M-20070240, NCT00647569
13.	Clinical Trial to Assess the Importance of Nephrectomy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P070144, NCT00930033
14.	Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Phase: Phase III Type: Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000668388, SWOG-S0931, S0931, NCT01120249
15.	Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EORTC-30073, EU-21022, PFIZER-EORTC-30073, NCT01099423
16.	A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113387, NCT01235962
17.	Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Phase: Phase III Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-00723, E2810, CDR0000730383, ECOG-E2810, U10CA021115, NCT01575548
18.	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AGS-003-007, 2012-000871-17, NCT01582672
19.	Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AP311736, NCT01599754
20.	Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 16037 / AN 33/11, 2011-004396-36, NCT01613846
21.	Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA209-025, 2011-005132-26, NCT01668784
22.	A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation Phase: Phase III Type: Treatment Status: Active Age: 20 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: E7040-J081-301, NCT01677624
23.	Stem Cell Transplant for Hematologic Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
24.	Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 4K-05-1, NCT00184015
25.	Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: immatureDC- HMO-CTIL, NCT00278018